| Name | Title | Contact Details |
|---|
Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration.
Lassen Therapeutics is developing novel, best-in-class biotherapeutics to improve the lives of patients suffering from serious diseases.
Sapphire Biotech, Inc.`s diagnostic tool is being used to study the company`s enzyme biomarker to detect pancreatic cancer earlier than circulating tumor cells.
EVIDENCE takes care of continuous education of investigators in clinical trials and takes every effort to help them keep a high level of practical knowledge of GCP (Good Clinical Practice) and other aspects of clinical trails. EVIDENCE offers GCP courses
M3 is a biopharmaceutical company focused on development of therapeutics to address Alzheimer`s, Parkinson`s and Neurodegeneration.